The U.S. Food and Drug Administration has approved Lipfendra, a new daily pill designed to lower "bad" cholesterol, marking a significant shift in how patients manage cardiovascular health. Developed by Merck, the medication is the first oral treatment in a class of drugs known as PCSK9 inhibitors. Until now, patients requiring this type of therapy had to rely on self-administered injections to achieve similar results. The approval provides a new, more convenient option for adults with high cholesterol, including those with an inherited condition called heterozygous familial hypercholesterolemia, to be used alongside diet and exercise.
Lipfendra works by blocking the PCSK9 protein, which naturally limits the liver's ability to remove low-density lipoprotein, or LDL, from the blood. By inhibiting this protein, the drug helps the liver clear cholesterol more effectively. Clinical trials indicated that the once-daily tablet could reduce LDL cholesterol levels by approximately 60 percent. This level of effectiveness is comparable to existing injectable therapies, which have been available for years but have sometimes faced challenges regarding patient adoption due to the requirement for needles.
This approval is particularly relevant for patients who cannot achieve their cholesterol goals with standard, low-cost statins or who experience side effects such as muscle pain or weakness from those traditional treatments. While statins remain the primary defense against heart disease for most people, the availability of an oral PCSK9 inhibitor offers a vital alternative for those at high risk of heart attack and stroke who need more intensive management.
Merck has stated that the drug will be available to patients in the coming weeks. The company has set a list price of $10.50 per day and plans to offer programs to help reduce out-of-pocket costs for both commercially insured and Medicare patients. While the drug has demonstrated success in lowering cholesterol, Merck is continuing to conduct studies to confirm that this reduction consistently translates into long-term clinical benefits, such as a decreased incidence of heart attacks and strokes.